Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Carrot
"You really need to stop posting complete and utter rubbish on this bb " - as opposed to half understood chunks of c&p?
Pots and kettles perhaps?
Carrot
As TG2D states; this really is desperate stuff, and not helped by your response. Have you ever thought about not posting? Remember the old adage; do not open mouth until brain is in gear. The same applies to posting.
Verbal diarrhoea, on and on and on with the same half digested facts. The Lucci paper is 3 years old. Who do you ramp for? Or is there an insatiable need to see yourself on the board upwards of 5 time a day? Pitiful.
Thompi
Sure, I appreciate that Parsortix is being used in the research setting for ovarian, lung, prostate, ? also NSCLC, with good results. When I mentioned a one trick pony, it was in reference to the FDA approval. I do not understand why the FDA should limit approval in this way, but such it is. Cynic that I am, I just wonder how easier it might have been for an American firm.
I understand that the hoops that have to be gone through for further approvals are much less onerous than the huge amount required for the initial approval for Ca breast, and I wonder why AGL have not done this. Cost perhaps?. I live in hope for AGL, but optimism thin just now.
Moab
Robizm
That is another important point. I think they may have one hell of a job getting FDA approval, and perhaps they intend not to bother. As there are quite a number of players in this market, with a broadly similar offering, there may be a price war which makes the cost more palatable without insurance cover.
Carrot
Parsortix has been approved for use with Ca breast. it is a one trick pony. Illumina et al have spent billions on a technique that covers all major cancers. Parsortix can only cover one of these. So they cannot, as you put it "do a complete check to see of the cancer in question has DNA ............" because they will not be allowed to in clinical use without further permissions from FDA. "Simples!!!!", as you so quaintly put it.
If anyone is credulous enough to believe any of the nonsense spouted by posters, here or elsewhere, and to make investment decisions based on it, then they deserve what they get.
MOAB
Thompi
The field is changing very rapidly and the analysis of cf DNA and CTC DNA from a single blood sample may be complementary and may provide the best of “both worlds”. I agree that the degree of overlap / utility between the two techniques is increasing, but it still seems fiendishly complex, with both concordance and discordance between DNA from each technique. I don't envy the researchers putting their findings into clinical practice, although there are plenty of papers to be written and reputations made!